ZIOPHARM Announces Four Presentations at the 2016 ASH

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ZIOPHARM Announces Four Presentations at the 2016 ASH Annual Meeting

BOSTON, Nov. 03, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP ), a biopharmaceutical company focused on new cancer immunotherapies, today announced that four abstracts highlighting data from the Company’s adoptive cell-based therapeutic programs have been accepted for presentation at the 58 th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held December 3-6, 2016 in San Diego.

The research, conducted at The University of Texas MD Anderson Cancer Center and Intrexon Corporation (NYSE: XON ) demonstrates, among other results, that T cells can be quickly produced with the Sleeping Beauty system and that this non-viral approach to gene therapy can be harnessed to generate chimeric antigen receptor (CAR) and T-cell receptor (TCR) expressing effector cells.

"This suite of nonclinical data underscores the technology underlying our adoptive cell-based programs, including the potential for the Sleeping Beauty platform to improve the manufacture of genetically modified T cells and our ability to redirect T-cell specificity to blood cancers and solid tumors using CARs and TCRs," said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of ZIOPHARM. "This research advances our plans to rapidly and cost-effectively deliver engineered T cells, and we look forward to seeing it translate into clinical programs."

Details for ASH presentations are as follows:

Title:    Very Rapid Production of CAR + T Cells upon Non-viral Gene Transfer using the Sleeping Beauty System Session Title: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation Date and Time: Sunday, December 4, 2016, 6:00 – 8:00 p.m. PT Publication ID: 2807 Location: San Diego Convention Center, Hall GH

Title: Personalization of T-cell Therapy using a High-throughput Platform to Identify Tumor-specific T-cell Receptors Session Title: 703. Adoptive Immunotherapy: Poster II Date and Time: Sunday, December 4, 2016, 6:00 – 8:00 p.m. PT Publication ID: 3359 Location: San Diego Convention Center, Hall GH

Title: Combination Immunotherapy with NY-ESO-1 Specific CAR + T Cells with T-Cell Vaccine Improves Anti-Myeloma Effect Session Title: 703. Adoptive Immunotherapy: Poster II Date and Time: Sunday, December 4, 2016, 6:00 – 8:00 p.m. PT Publication ID: 3366 Location: San Diego Convention Center, Hall GH

Title: Chimeric Antigen Receptor-Modified T Cells for the Treatment of Acute Myeloid Leukemia Expressing CD33 Session Title: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III Date and Time: Monday, December 5, 2016, 6:00 – 8:00 p.m. PT Publication ID: 4058 Location: San Diego Convention Center, Hall GH

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE: XON ) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.

Forward-Looking Safe-Harbor Statement:

This press release contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the Company's plans and expectations regarding its securities offerings, fundraising activities and financial strategy, the progress, timing and results of preclinical and clinical trials involving the Company's drug candidates, and the progress of the Company's research and development programs. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to finance our operations and business initiatives and obtain funding for such activities, whether chimeric antigen receptor T cell (CAR T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, or any of our other therapeutic candidates will advance further in the pre-clinical or clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether chimeric antigen receptor T cell (CAR T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, and our other therapeutic products will be successfully marketed if approved; the strength and enforceability of our intellectual property rights; competition from other pharmaceutical and biotechnology companies; and the other risk factors contained in our periodic and interim SEC reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and our Quarterly Report for the quarter ended June 30, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Trademarks

RheoSwitch Therapeutic System ®  (RTS ® ) technology is a registered trademark of Intrexon Corporation.

Contact: Lori Ann Occhiogrosso ZIOPHARM Oncology, Inc. 617-259-1987 locchiogrosso@ziopharm.com David Pitts Argot Partners 212-600-1902 david@argotpartners.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 45

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 327

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Arbor Realty Trust Faces Securities Fraud Allegations

Updated Category News Views 108

Securities Lawsuit Against Arbor Realty Trust Looms Well, here we go again. Another day, another securities lawsuit hitting the headlines. This time it's Arbor Realty Trust (NYSE: ABR) getting caught in the crossfire, accused of pulling the wool over investors' eyes. Seems like 'truth in advertising' is just part of the PR playbook for some big shots. Understanding the...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 110

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 17

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 226

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 0

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 179

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 124

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 268

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting New Dining and Shopping Experiences Coming to Cotino

Updated Category News Views 309

Exciting Developments at Cotino Bay Beach A vibrant new community is set to emerge with the opening of Cotino Bay Beach, Dining and Shops in fall 2026. The first Storyliving by Disney community is gearing up to offer an array of dining and retail experiences, creating a unique destination for residents and visitors alike. Restaurants to Enrich the Community Among the...

Continue Reading
dsm-firmenich Expands Share Repurchase Program for Growth

Updated Category News Views 227

Introduction to the Share Repurchase Program dsm-firmenich, a leader in nutrition, health, and beauty, has embarked on a significant share repurchase program with the aim of enhancing shareholder value and strategically managing its capital. By initiating this buyback, dsm-firmenich demonstrates its commitment to returning value to its investors while still investing in...

Continue Reading
Investigation into Arvinas, Inc. Over Securities Fraud Claims

Updated Category News Views 561

Investigation of Arvinas, Inc. Pomerantz LLP is looking into potential claims on behalf of investors of Arvinas, Inc. (NASDAQ: ARVN). This investigation aims to uncover whether the company and its executives may have engaged in securities fraud or other illegal business practices. Recent Developments Arvinas has recently communicated significant changes to its clinical...

Continue Reading
Gantry Enhances Mortgage Banking with Triad Capital Acquisition

Updated Category News Views 145

Gantry got its hands on Triad Capital Advisors back in 2023, and it was no small move. This merger wasn't just about beefing up their operational muscle; it expanded Gantry's footprint in the Midwest finance scene big time. It’s like they dropped a bomb on their competitors without warning—traders watching closely could feel the shift coming. With this acquisition,...

Continue Reading
Port Athena Debuts with PENETRON Solution in Tartu

Updated Category News Views 32

The Emergence of Port Athena in Tartu Move over, sleepy towns—Tartu's staking its claim with the Port Athena development. What we're looking at is more than just another block of buildings. It's practically a new district, nestled on the banks of the Emajõgi River. Forget the stereotypical old-world charm; we're talking sleek, modern architecture that's ready to become...

Continue Reading